Raymond James Initiates Coverage On Health Catalyst with Strong Buy Rating, Announces $46 Price Target

Raymond James analyst John Ransom initiates coverage on Health Catalyst (NASDAQ:HCAT) with a Strong Buy rating and a $46 price target.

Benzinga · 12/20/2019 11:56

Raymond James analyst John Ransom initiates coverage on Health Catalyst (NASDAQ:HCAT) with a Strong Buy rating and a $46 price target.